<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04646187</url>
  </required_header>
  <id_info>
    <org_study_id>202000261</org_study_id>
    <secondary_id>2020-001811-26</secondary_id>
    <nct_id>NCT04646187</nct_id>
  </id_info>
  <brief_title>De-escalation of Anti-TNF Therapy in Inflammatory Bowel Disease</brief_title>
  <acronym>FREE</acronym>
  <official_title>De-escalation of Anti-TNF Therapy in Adolescents and Young Adults With IBD With Tight Faecal Calprotectin and Trough Level Monitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Crohn´s and Colitis Organisation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bühlmann Laboratories AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Groningen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BACKGROUND/RATIONALE:&#xD;
&#xD;
      Treatment outcomes of patients with inflammatory bowel disease (IBD) have improved enormously&#xD;
      during the past decade due to the use of anti-tumour necrosis factor (anti-TNF) therapy. As a&#xD;
      result, 67 to 91% of paediatric patients and 66% of adult patients is still in sustained&#xD;
      remission two years after the initiation of anti-TNF therapy. Prolonged use of anti-TNFs&#xD;
      comes with disadvantages such as dose dependent susceptibility to infections and&#xD;
      dermatological adverse effects. Preliminary, mostly uncontrolled studies suggest that dose&#xD;
      reduction by dosing interval lengthening is a realistic option in a relevant proportion of&#xD;
      patients with IBD, provided that intensive follow-up is applied.&#xD;
&#xD;
      OBJECTIVE:&#xD;
&#xD;
      To evaluate whether a faecal calprotectin (FC) guided strategy of anti-TNF dosing interval&#xD;
      lengthening is non-inferior in maintaining remission in patients with IBD, compared with an&#xD;
      unchanged dosing interval.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY DESIGN:&#xD;
&#xD;
      International, multi-centre, prospective, partially randomised patient-preference trial.&#xD;
&#xD;
      STUDY POPULATION:&#xD;
&#xD;
      Study population: Eligible patients are aged 12-25 years with luminal Crohn's disease (CD) or&#xD;
      ulcerative colitis (UC), who have three consecutive faecal calprotectin (FC) results in the&#xD;
      target range (i.e. &lt;250 µg/g for CD patients; &lt;150 µg/g for UC patients) over a period of 6&#xD;
      months at study entry or recently confirmed endoscopic remission.&#xD;
&#xD;
      DE-ESCALATION STRATEGY:&#xD;
&#xD;
      In patients treated with adalimumab, the dosing interval will be lengthened from 2 to 3&#xD;
      weeks. In patients treated with infliximab, the dosing interval will be lengthened from 8 to&#xD;
      12 weeks. FC rapid tests will be performed every 4 weeks and rapid tests for anti-TNF trough&#xD;
      levels will be performed every 12 weeks.&#xD;
&#xD;
      MAIN STUDY ENDPOINTS:&#xD;
&#xD;
      The primary outcome is the cumulative incidence of out-of-range FC results at 48 weeks&#xD;
      follow-up. Secondary endpoints include time to get out-of-range FC results, cumulative&#xD;
      incidence of anti-TNF associated adverse effects, proportion of patients progressing from&#xD;
      out-of-range FC to loss-of-response and identification of predictors of successful&#xD;
      de-escalation.&#xD;
&#xD;
      ETHICAL CONSIDERATIONS:&#xD;
&#xD;
      Patients with reduced anti-TNF exposure may have a higher risk of out-of-range FC results&#xD;
      and, on the other hand, may benefit from fewer hospital visits or injections and possibly a&#xD;
      decrease in adverse effects of anti-TNF therapy. Tight monitoring of FC levels (i.e.&#xD;
      4-weekly) will allow institution of re-escalation before the patient manifests clinical signs&#xD;
      of relapse. This study cannot be conducted without the participation of minors and young&#xD;
      adults, who typically have a short disease duration. Early treatment with anti-TNF agents&#xD;
      possibly modifies the course of their disease, which makes provision for safe deescalation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>cumulative incidence of out-of-range fecal calprotectin results at 48 weeks follow-up</measure>
    <time_frame>48 weeks</time_frame>
    <description>Out-of-range FC results are defined as fecal calprotectin above the target range (i.e. &gt;250 μg/g for CD patients; &gt;150 μg/g for UC patients) and at least 100 μg/g increase compared with the previous result, unless the previous result was already above the target range.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to get out-of-range fecal calprotectin results</measure>
    <time_frame>up to 48 weeks</time_frame>
    <description>The time from study baseline until the first out-of-range fecal calprotectin result</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of anti-TNF-associated respiratory infections and dermatological adverse effects at 48 weeks follow-up</measure>
    <time_frame>48 weeks</time_frame>
    <description>Dermatological adverse effect include skin infections, new-onset or worsening of psoriasis, psoriasiform lesions, eczema, acne and alopecia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of FC and anti-TNF trough levels in the first 16 weeks after reverting to previous dosing interval</measure>
    <time_frame>Up to 48+16 weeks</time_frame>
    <description>Proportion of patients with return of FC levels to target range without switch to out-of-class biological</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients developing loss-of-response in the first 16 weeks after reverting to the previous dosing interval</measure>
    <time_frame>Up to 48+16 weeks</time_frame>
    <description>Loss-of-response is defined as the appearance of symptoms of active IBD in combination with persistent out-of-range fecal calprotectin results</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Identification of predictors of successful de-escalation.</measure>
    <time_frame>48 weeks</time_frame>
    <description>Predictors of successful de-escalation will be assessed by calculating odds ratios with the use of univariate logistic regression analysis. Candidate predictors with p&lt;0.10 in univariate analysis will be selected for use in the multivariate analysis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patients' attitudes towards deprescribing anti-TNF agents</measure>
    <time_frame>48 weeks</time_frame>
    <description>We will use the revised Patients' Attitudes Towards Deprescribing (rPATD) questionnaire</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Crohn Disease</condition>
  <condition>Colitis, Ulcerative</condition>
  <arm_group>
    <arm_group_label>Intervention group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In patients treated with adalimumab, the dosing interval will be lengthened from 2 to 3 weeks. In patients treated with infliximab, the dosing interval will be lengthened from 8 to 12 weeks. Consists of two groups: Patients randomised to the intervention group and patients allocated to the intervention group based on preference.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Unchanged dosing interval. Consists of two groups: Patients randomised to the control group and patients allocated to the control group based on preference.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <description>Dosing interval lengthening from 8 to 12 weeks</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Remicade</other_name>
    <other_name>Flixabi</other_name>
    <other_name>Inflectra</other_name>
    <other_name>Remsima</other_name>
    <other_name>Zessly</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Dosing interval lengthening from 2 to 3 weeks</description>
    <arm_group_label>Intervention group</arm_group_label>
    <other_name>Humira</other_name>
    <other_name>AMGEVITA</other_name>
    <other_name>Hulio</other_name>
    <other_name>Hyrimoz</other_name>
    <other_name>Idacio</other_name>
    <other_name>Imraldi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 12-25 years&#xD;
&#xD;
          -  Diagnosed with luminal Crohn's disease or ulcerative colitis&#xD;
&#xD;
          -  Treated with either 8-weekly infliximab or 2-weekly adalimumab&#xD;
&#xD;
          -  Current anti-TNF agent as first ever anti-TNF agent or prior anti-TNF agent&#xD;
             discontinued for reason other than primary non-response or secondary loss-of-response&#xD;
&#xD;
          -  No previous attempts to lengthen the dosing interval&#xD;
&#xD;
          -  Three consecutive faecal calprotectin (FC) results in the target range (i.e. &lt;250 μg/g&#xD;
             for CD patients; &lt;150 μg/g for UC patients) in the previous 6 months or confirmed&#xD;
             endoscopic remission within 2 months before study entry (i.e. simple endoscopic score&#xD;
             for Crohn's disease (SES-CD) &lt;3 points for CD patients; ulcerative colitis endoscopic&#xD;
             index of severity (UCEIS) ≤1 point for UC patients)&#xD;
&#xD;
          -  Absence of symptoms associated with active IBD (judged by the local IBD-team)&#xD;
&#xD;
          -  Written informed consent granted&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Perianal fistula&#xD;
&#xD;
          -  Presence of ileostomy or ileoanal pouch (as FC cut-off is not validated for small&#xD;
             bowel faeces)&#xD;
&#xD;
          -  Any inflammatory comorbidity, such as rheumatoid arthritis&#xD;
&#xD;
          -  Current treatment with corticosteroids (prednisone or budesonide)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick F van Rheenen, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Medical Center Groningen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrick F van Rheenen, MD PhD</last_name>
    <phone>050 3614151</phone>
    <phone_ext>+31</phone_ext>
    <email>p.f.van.rheenen@umcg.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marleen Bouhuys, MD MsC</last_name>
    <email>m.bouhuys@umcg.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie van Biervliet, Prof MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Stephanie van Biervliet, Prof MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Triana Lobatón Ortega, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier universitaire de Liège</name>
      <address>
        <city>Liège</city>
        <zip>B-4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Edouard Louis, Prof MD PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrick F van Rheenen, MD PhD</last_name>
      <phone>050 3614151</phone>
      <phone_ext>+31</phone_ext>
      <email>p.f.van.rheenen@umcg.nl</email>
    </contact>
    <contact_backup>
      <last_name>Marleen Bouhuys, MD MsC</last_name>
      <email>m.bouhuys@umcg.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Patrick F van Rheenen, Md PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerard Dijkstra, Prof MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>L'Hospitalet De Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jordi Guardiola, MD PhD</last_name>
    </contact>
    <investigator>
      <last_name>Jordi Guardiola, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 20, 2020</study_first_submitted>
  <study_first_submitted_qc>November 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 27, 2020</study_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Groningen</investigator_affiliation>
    <investigator_full_name>P.F. van Rheenen</investigator_full_name>
    <investigator_title>MD PhD</investigator_title>
  </responsible_party>
  <keyword>Infliximab</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Tumor Necrosis Factor-alpha</keyword>
  <keyword>Inflammatory Bowel Diseases</keyword>
  <keyword>Crohn Disease</keyword>
  <keyword>Colitis, Ulcerative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

